1
. The activity of myeloid cells such as macrophages and neutrophils is likewise regulated by a balance between stimulatory and inhibitory signals. In particular, cell surface expression of the CD47 protein creates a 'don't eat me' signal on tumor cells by binding to SIRPα expressed on myeloid cells [2] [3] [4] [5] . Using a haploid genetic screen, we here identify glutaminyl-peptide cyclotransferase-like protein (QPCTL) as a major component of the CD47-SIRPα checkpoint. Biochemical analysis demonstrates that QPCTL is critical for pyroglutamate formation on CD47 at the SIRPα binding site shortly after biosynthesis. Genetic and pharmacological interference with QPCTL activity enhances antibody-dependent cellular phagocytosis and cellular cytotoxicity of tumor cells. Furthermore, interference with QPCTL expression leads to a major increase in neutrophil-mediated killing of tumor cells in vivo. These data identify QPCTL as a novel target to interfere with the CD47 pathway and thereby augment antibody therapy of cancer.
CD47 is a broadly expressed inhibitory ligand for myeloid cells 4, 6 . However, CD47 expression on tumor cells can be greater than on surrounding healthy tissue cells, providing a first rationale for the clinical targeting of this myeloid cell checkpoint 3, 7 . In addition, prophagocytic signals such as calreticulin and SLAMF7 can be expressed on the surface of cancer cells 8, 9 , leading to increased phagocytosis and clearance of these cells upon CD47-SIRPα blockade. Finally, prophagocytic signals can also be provided by therapy, in particular by administration of opsonizing tumor-specific antibodies, such as the anti-CD20 rituximab, anti-Her2 trastuzumab and anti-EGFR cetuximab. In support of this strategy, preclinical data have demonstrated that targeting of the CD47-SIRPα axis in combination with tumor-opsonizing antibodies leads to increased tumor control [10] [11] [12] . Recent work has provided the first clinical validation of the CD47-SIRPα axis as a myeloid checkpoint by demonstrating a 50% objective response rate of the combination of rituximab and anti-CD47 in rituximab-refractory non-Hodgkin's lymphoma 13 . Despite the potential value of the CD47 checkpoint molecule as a therapeutic target, transcriptional control by the Myc oncogene is thus far the only identified regulatory mechanism of CD47's protein expression or function 14 . To reveal novel genetic determinants of CD47-SIRPα binding, we performed a FACS-based haploid genetic screen using an antibody to human CD47 (αhCD47-CC2C6) that binds to the SIRPα recognition site 15 . Analysis of gene-trap integration sites in cells with impaired αhCD47-CC2C6 binding revealed two strong hits, the CD47 gene itself and the gene encoding glutaminyl-peptide cyclotransferase-like protein (QPCTL, isoQC) ( Fig. 1a ; see Supplementary Table 1 for a full overview of screen results). QPCTL has been described as a Golgi-resident enzyme 16 that, like its secreted family member QPCT, can catalyze the cyclization of N-terminal glutamine and glutamic acid residues on target proteins into an N-terminal pyroglutamate residue (pGlu) 17, 18 . Pyroglutamate modification of proteins by QPCT has been implicated in Huntington's disease 19 and Alzheimer's disease [20] [21] [22] . Notably, crystallographic analysis of the CD47 protein has demonstrated the presence of an N-terminal pyroglutamate that, based on its hydrogen bonding, is considered to be involved in SIRPα binding 23 . However, this pyroglutamate is assumed to be formed spontaneously upon cleavage of the CD47 signal sequence 24 .
To determine how QPCTL influences the CD47 protein, we generated CD47-deficient and QPCTL-deficient HAP1 cells. -CC2C6 lo channel) for each gene. Light-blue and orange dots indicate genes with significant enrichment of insertions within the CD47-CC2C6 hi and CD47-CC2C6 lo populations, respectively. Green dots represent CD47 and QPCTL. Significant enrichment of insertions (total insertions n = 3,254,889) was determined by two-sided Fisher's exact test with multiple comparison correction (false discovery rate (FDR)-corrected P < 0.05). MI, mutation index. b, Flow cytometry plot of surface binding of anti-human CD47 antibody clone B6H12 (αhCD47-B6H12) and αhCD47-CC2C6 to HAP1 wild type (WT), CD47 knockout (KO) and QPCTL KO (cl21) cells. Data represent two independent experiments with similar results (n = 3 biological replicates per experiment). c, Cell surface binding of anti-human CD47 antibody clone 2D3 (αhCD47-2D3), αhCD47-B6H12 and αhCD47-CC2C6 to HAP1 WT, CD47 KO 
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As we expected, CD47 deficiency led to impaired binding of both recombinant human SIRPα (hSIRPα-Fc) and all antibodies to CD47 we tested (αhCD47-CC2C6, αhCD47-2D3 and αhCD47-B6H12).
In contrast, knockout of QPCTL selectively affected binding of recombinant hSIRPα and αhCD47-CC2C6, whereas overall cell surface CD47 levels, as determined using other antibodies to CD47 (αhCD47-2D3 and αhCD47-B6H12), remained unaltered ( Fig. 1b-d) . The role of QPCTL as a modifier of CD47 was not restricted to HAP1 but was likewise observed in malignant melanoma (A375), epidermoid carcinoma (A431), lung cancer (A549), colorectal cancer (DLD1) and rectal carcinoma (RKO) cancer cells ( Fig. 1e and Extended Data Fig. 1a ). Low-level residual binding of monomeric hSIRPα protein to QPCTL knockout cells was observed only at high concentrations, indicating that the binding affinity of SIRPα to CD47 depends to a large extent on QPCTL (Extended Data Fig. 1b,c) . Binding of SIRPγ, a CD47 ligand without known signaling function that is primarily expressed on T cells 25 , was likewise affected by QPCTL deficiency (Extended Data Fig. 1d,e) . Reconstitution experiments demonstrated that the CD47-modifying activity of QPCTL is encoded by QPCTL transcript variant 1 (Extended Data Fig. 2a-d) , and introduction of a catalytically dead QPCTL variant (D326E, generated based on homology with QPCT) 26 demonstrated that the enzymatic activity of QPCTL is essential for its role as a CD47 modifier (Extended Data Fig. 2e,f) .
To assess where in the protein life cycle CD47 is modified by QPCTL, we analyzed the fate of CD47 molecules in wild-type and QPCTL-knockout melanoma cells transduced with an hemagglutinin-tagged CD47 gene product with pulse-chase analysis.
Comparison of immunoprecipitates obtained with αhCD47-CC2C6 and αhCD47-B6H12 revealed a selective loss of the CD47 conformation recognized by αCD47-CC2C6 in QPCTL-deficient cells (Fig. 2a) . Notably, at all time points we analyzed, no discernible levels of CD47 protein were isolated by αhCD47-CC2C6, indicating that pyroglutamate formation on CD47 depends strictly on QPCTL and does not involve an appreciable level of spontaneous conversion. QPCTL-mediated CD47 modification occurs very early in the protein life cycle. This was demonstrated by the presence of αhCD47-CC2C6-reactive CD47 molecules that are sensitive to deglycosylation by endoglycosidase H, indicating residence in the endoplasmic reticulum or early Golgi (Fig. 2a) , and by the fact that the maximal level of pyroglutamate-modified CD47 is already reached after a 10-min labeling (Fig. 2b) . To reveal possible additional regulators of formation of the SIRPα binding site with high sensitivity, we performed a two-dimensional genetic screen (see Extended Data Fig. 3a) to distinguish genes that influence binding of both αhCD47-CC2C6 and αhCD47-B6H12 (for example, general CD47 protein regulators) from genes that influence binding of αhCD47-CC2C6 but not αhCD47-B6H12 (for example, selective regulators of the SIRPα binding site). This screen confirmed the role of QPCTL as a regulator of the the SIRPα binding site, but also identified HSPA13, which encodes the heat shock protein HSPA13, as a modifier of αhCD47-CC2C6 binding, but not αhCD47-B6H12 binding (Extended Data Fig. 3b-e ). HSPA13 has been described as an endoplasmic reticulum-resident protein 27 , consistent with a possible role of HSPA13 in regulating the efficiency of CD47 modification by QPCTL.
To prevent the generation of pathogenic pyroglutamatemodified proteins implicated in Huntington's disease and Alzheimer's disease by the QPCTL family member QPCT, glutaminyl cyclase inhibitors have been developed and are undergoing clinical evaluation 19, 28, 29 . To determine whether small molecule inhibition of QPCTL could be used to influence CD47 binding to SIRPα, we selected two QPCT inhibitors that inhibit QPCTL with high efficiency 19, 30 . Treatment with the glutaminyl cyclase inhibitor SEN177 (half-maximum inhibitory concentration of 0.013 μM for QPCTL) reduced hSIRPα-Fc staining for eight of eight cell lines tested (Fig. 3a,b and Extended Data Fig. 4a ), and to the same extent as QPCTL gene deletion (Fig. 1c-e and Extended Data Fig. 1a) , whereas CD47 surface levels remained unaffected. Treatment with the glutaminyl cyclase inhibitor PQ912 yielded similar results (Extended Data Fig. 4b,c) .
Upon cyclization of an N-terminal residue to form a pyroglutamate, a leaving amino group is replaced by a hydroxyl group 31 , thereby altering the isoelectric point of the molecule. We used one-dimensional isoelectric focusing (1D-IEF) to visualize this alteration of the isoelectric point of hemagglutinin-tagged CD47 in wild-type and QPCTL-knockout A375 melanoma cells. CD47 from QPCTL-knockout cells was characterized by an increased isoelectric point as compared to CD47 from wild-type cells (Fig. 3c) . Furthermore, treatment with SEN177 increased the isoelectric point of CD47 present in wild-type cells to that of QPCTL-knockout cells, but did not affect the isoelectric point of CD47 molecules isolated from QPCTL-knockout cells. As a second approach to assess to what extent CD47 modification could be influenced by small molecule inhibition, we performed western blot analysis of immunoprecipitates of hemagglutinin-tagged CD47 from untreated or SEN177-treated cells. In line with the IEF data, treatment with SEN177 led to a near-complete inhibition of pGlu-CD47 formation (Fig. 3d) . Finally, SEN177 treatment of QPCTL-deficient lung cancer (A549) and epidermoid carcinoma (A431) cells did not 
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further reduce SIRPα binding (Extended Data Fig. 4d,e) . Together these data demonstrate (1) that QPCTL activity is critical for the formation of pGlu-modified CD47, (2) that glutaminyl cyclase inhibitors alter the CD47 protein by inhibiting QPCTL function and (3) that the resulting block in pGlu-modified CD47 is near complete.
A hypothesis arising from the above data is that QPCTL deletion or inhibition could limit signaling through the CD47-SIRPα axis, thereby enhancing the capacity of macrophages and neutrophils to kill opsonized tumor cells by antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC). In vitro phagocytosis assays revealed that SEN177 treatment increased antibody-dependent cellular phagocytosis of anti-CD20-treated Burkitt's lymphoma (Raji) cells by human macrophages to the same or a greater extent than treatment with the combination of rituximab and the SIRPα-blocking agent 12C4, or the combination of rituximab and the CD47-blocking agent B6H12 F(ab′) 2 (ref. 7 ; Fig. 3e , Extended Data Fig. 5 and Extended Data Fig. 6a ). Likewise, both SEN177 treatment and knockout of QPCTL increased neutrophilmediated ADCC of EGFR-expressing A431 epidermoid carcinoma cells in the presence of the EGFR-specific antibody cetuximab ( Fig. 3f and Extended Data Fig. 6b,c) . Thus, inhibition or deletion of QPCTL leads to increased killing of target cells by both human neutrophils and macrophages, indicating functional disruption of the CD47-SIRPα inhibitory pathway.
The role of QPCTL as a modifier of the CD47 protein is conseved in mice. Specifically, deletion of QPCTL in either B16F10 melanoma cells or Ba/F3 pro-B cells reduced binding of murine SIRPα (mSIRPα-Fc), and this could be restored by lentiviral overexpression of QPCTL (Extended Data Fig. 7a,b) . Likewise, treatment with SEN177 led to reduced binding of SIRPα without altering total CD47 surface levels (Extended Data Fig. 7c ). Next, we used Ba/F3 cells that express human Her2 to evaluate whether inhibition of pyroglutamate formation could increase killing of tumor cells by human neutrophils in the presence of anti-Her2. Similar to what we observed for human target cells, both QPCTL knockout and SEN177 treatment synergized with anti-Her2 treatment to induce neutrophilmediated lysis of tumor cells (Fig. 4a,b and Extended Data Fig. 7d ). The killing efficiency of CD47-and QPCTL-deficient tumor cells by neutrophils was not further enhanced by SEN177 treatment, demonstrating that the functional effects of SEN177 depend on the CD47 pathway (Extended Data Fig. 7e ). The same effects of QPCTL deletion and small molecule inhibition were observed when using murine immune cells isolated from whole blood as effector cells (Extended Data Fig. 7f,g ). Fig. 8a ). In PBS-treated mice, the ratio of QPCTL deficient cells versus wild-type cells remained constant, indicating that QPCTL does not influence short-term tumor cell engraftment. In contrast, in mice treated with anti-Her2, we observed much greater killing of QPCTL-deficient tumor cells than wild-type cells (ratio of wild type/QPCTL-deficient cells in anti-Her2-treated mice of 10:1) (Fig. 4c,d and Extended Data Fig. 8b) . Notably, the enhanced tumor cell killing achieved by blockade of pyroglutamate formation was similar to that achieved by full genetic deficiency of the CD47 checkpoint (Extended Data Fig. 8c,d ); this was also observed when CD47-and QPCTL-deficient tumor cells were co-injected (Fig. 4e) . The selective killing of QPCTL-(and CD47)-deficient cells in antiHer2-treated mice was accompanied by a large influx of neutrophils, suggesting a positive feedback loop that enhances antitumor immunity ( Fig. 4f and Extended Data Fig. 9a,b) . Similarly, injection of QPCTL-deficient cells into anti-Her2-treated mice led to a profound increase in neutrophils relative to recipients of wild-type cells, with only small changes in T cell populations (Extended Data Fig. 9c,d) . Notably, the selective killing of QPCTL-deficient cells in anti-Her2-treated mice was largely abrogated by pretreatment with anti-Ly6G (Fig. 4g) , indicating that neutrophils are the dominant effector cells that eliminate QPCTL-deficient cells in this model. In solid tumor models, activity of CD47 blockade depends on both innate immune cells and T cells [33] [34] [35] [36] . It remains to be established whether in vivo QPCTL inhibition alters intratumoral T cell activity. However, as shown by a series of in vitro assays, the expansion, differentiation, cytokine production and killing capacity of human T cells is compatible with small molecule inhibition of QPCTL (Extended Data Fig. 10 ).
We conclude that QPCTL is a critical modifier of the CD47 protein and, as such, a regulator of the CD47-SIRPα pathway. Prior research provides strong evidence that targeting of the CD47 axis 
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can promote tumor control by both innate and adaptive immune cells, and clinical development of CD47 antagonists is ongoing 13, 37 . The poor pharmacokinetics of SEN177 in mice (a drop in serum concentration of ~1,000-fold in an 8-h time period, data not shown), precludes in vivo experiments using this inhibitor, but we hope to assess whether pharmacological manipulation of QPCTL activity with other existing 30 or novel inhibitors can be used to promote tumor immunity. CD47 molecules in tumor cells in which pGlu formation is blocked do display a low remaining affinity for SIRPα, as shown by residual binding of monomeric SIRPα at high concentration. However, blockade of pGlu formation enhances antitumor activity of myeloid cells to a similar extent as antibody 
Letters NaTURE MEDICINE blockade of CD47 or SIRPα (Fig. 3e,f) , and deletion of CD47 and QPCTL likewise leads to comparable tumor control in vivo ( Fig. 4e) , suggesting that this residual affinity does not have significant functional effects. Furthermore, QPCTL inhibitors should not be affected by the described antigen sink of anti-CD47 therapy owing to CD47 expression on erythrocytes and other cells 34 . In addition, the fact that CD47 molecules that newly arrive at the cell surface upon QPCTL inhibition already lack the pGlu modification may be an advantage relative to antagonistic antibodies that need to compete with SIRPα in the tumor microenvironment. Phase 1 or 2a studies that evaluate QPCT or QPCTL inhibitors for the treatment of neurodegenerative diseases have not revealed any significant toxicities 30, 38 , and the development of QPCTL inhibitors that may be used in isolation or in combination with CD47-blocking antibodies is a useful goal. Finally, it is notable from a biological perspective that human and parasitic genomes encode pyroglutamate aminopeptidases that can remove N-terminal pyroglutamate residues from proteins 39,] and that stimulation with lipopolysaccharide leads to increased expression of pyroglutamate aminopeptidase 1 (ref.
40
).
Whether such aminopeptidases can act as external modifiers of the CD47-SIRPα signaling pathway remains to be established.
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Methods
Haploid genetic flow cytometry-based screen. To identify genetic modulators of CD47, as measured by binding of the anti-human CD47 antibody CC2C6 (αhCD47-CC2C6), which recognizes the SIRPα binding site, mutagenized HAP1 cells were prepared using gene-trap retrovirus expressing blue fluorescent protein as described 41 . Briefly, 50 million HAP1 cells were seeded and transduced with virus from two combined harvests on three consecutive days in the presence of 8 µg ml -1 protamine sulfate (Sigma). The mutagenized cell library was then expanded to 30 T175 flasks at a confluence of ~80%. Subsequently, cells were dissociated with trypsin, washed once with PBS (Lonza) and stained with FITC-labeled αhCD47-CC2C6 (Biolegend) at a 1:80 dilution for 30 min in 20 ml PBS containing 0.5% (w/v) BSA (Sigma) and 0.2% (w/v) sodium azide (Sigma) at 4 °C, while protected from light. Subsequently, cells were washed three times with PBS containing 10% FCS and stained with FITC-labeled polyclonal goat anti-mouse IgG (Poly4053, Biolegend) at a 1:100 dilution for 30 min in PBS containing 0.5% (w/v) BSA and 0.2% (w/v) sodium azide at 4 °C while protected from light. After two washes with PBS containing 10% FCS and one wash with PBS, cells were fixed with BD Fix Buffer I (BD Biosciences) for 10 min at 37 °C. After two washes with PBS containing 10% FCS, cells were filtered through a 40-µm strainer (BD Falcon) before isolation of the two cell populations of interest (for example, CD47-CC2C6 lo and CD47-CC2C6 hi ) by FACS. Specifically, the first cell population, referred to as CD47-CC2C6 lo , constitutes the approximately 1-2% of cells with the lowest level of αCD47-CC2C6 binding. The second cell population, referred to as CD47-CC2C6 hi , constitutes the approximately 1-2% of cells with the highest level of αCD47-CC2C6 binding. To reduce potential confounding effects of diploid cells that are heterozygous for alleles carrying gene-trap integrations, cell sorting was restricted to cells with a 1n DNA content, as determined by staining with propidium iodide (Life Technologies). Cell sorting was carried out on a Biorad S3 Cell sorter until ~10 million cells were collected for each population. Sorted cells were pelleted and genomic DNA was isolated using a DNA mini kit (Qiagen), according to the manufacturer's protocol. To assist decrosslinking of genomic DNA, cell pellets were resuspended in PBS supplemented with proteinase K (Qiagen) followed by overnight incubation at 56 °C in lysis buffer AL (Qiagen) with agitation. Insertion sites present in both sorted cell populations were amplified and mapped to the human genome as described 41 , using a linear amplification polymerase chain reaction on the total yield of isolated genomic DNA. Samples were submitted for deep sequencing and gene-trap insertion sites were mapped and analyzed as follows: insertion sites were retrieved from trimmed reads (50 bases) that aligned unambiguously to human genome assembly Hg19 using Bowtie 42 allowing one mismatch. Using intersectBed, aligned reads were mapped to nonoverlapping Refseq gene coordinates. Intragenic gene-trap insertions in sense orientation within their genes were considered disruptive and kept for further analysis. For each gene, the number of unique disruptive insertions was compared between the CD47-CC2C6 lo and CD47-CC2C6 hi populations. Genes that were significantly enriched for insertions in either of the two populations (two-sided Fisher's exact test with Benjamini-Hochberg multiple testing correction, P < 0.05) were considered as regulators of CD47-CC2C6 binding. To reflect the directionality of the effect on CD47 abundance, a mutational index score was calculated as follows:
For genes for which disruptive insertions were identified in only one of the two populations, one insertion was assigned to the other population to allow inclusion of these genes in visualization plots.
For the 'four-way sort' genetic screen, cells were double-stained with allophycocyanin (APC)-labeled αhCD47 antibody B6H12 (αhCD47-B6H12) (eBioscience) and FITC-labeled αhCD47-CC2C6 (BioLegend) at a 1:80 dilution in 30 ml PBS containing 10% FCS for 60 min at 4 °C, while protected from light. Cells were washed once with ice-cold PBS containing 10% FCS and once with ice-cold PBS. Cells were then fixed with BD Fix buffer I for 10 min at 37 °C, washed once with PBS containing 10% FCS, and stained for 5 min at room temperature in PBS containing 10% FCS with 1 μg ml -1 DAPI (Invitrogen) for visualization of cells in G1 phase. Cells were washed once in PBS containing 10% FCS and filtered through a 40-μm strainer before the populations of interest were sorted on a BD FACSAria II. Specifically, the 1-2% of cells exhibiting the highest (B6H12 44 . NKIRTIL006 cell line was generated from a patient treated at the Netherlands Cancer Institute.
HAP1 cells were cultured in IMDM (Thermo Fisher Scientific) supplemented with 10% FCS (Sigma), 100 U ml -1 penicillin (Roche) and 100 μg ml -1 streptomycin (Roche) (penicillin-streptomycin) and l-glutamine. NKIRTIL006 cells were cultured in IMDM supplemented with 10% FCS and penicillin-streptomycin. A375, A549 and B16F10 cells were cultured in DMEM supplemented with 10% FCS and penicillin-streptomycin. A431, DLD1, Raji and JY cells were cultured in RPMI supplemented with 10% FCS and penicillin-streptomycin. Ba/F3-Her2 cells were cultured in RPMI supplemented with 10% FCS, penicillin-streptomycin, 0.2 ng ml -1 mouse IL-3 (Immunotools) and 5.0 μg ml -1 puromycin. SKBR3 cells were cultured in IMDM supplemented with 20% FCS and 100 U ml -1 penicillinstreptomycin. Cells were cultured at 37 °C and 5% CO 2 . Measurements were performed on an LSRII, LSRFortessa or FACSCantoII (BD Biosciences). Data were analyzed using FACS Diva software (BD Biosciences) or FlowJo software.
Vector generation. The cDNA of the two human transcript variants of QPCTL, glutaminyl-peptide cyclotransferase-like transcript 1 (QPCTL(1), RefSeq: NM_017659.3) and glutaminyl-peptide cyclotransferase-like transcript 2 (QPCTL(2), RefSeq: NM_001163377.1), were ordered as codon-optimized gBlock gene fragments (IDT DNA) encoding an N-terminal FLAG tag. QPCTL(1) comprises seven exons, whereas QPCTL(2) comprises six exons and lacks exon 3, which encodes the amino acid s eq ue nce F LE ATLRSLTAGWHVELDPFTAST PLGPVDFGNVVATLDPRAARHLTLACHYDSKLFPPGSTPFVGATDSAVPCA LLLELAQALDLELSRAKKQ. The cDNA of the Mus musculus transcript variant of QPCTL (mQPCTL, RefSeq: NM_026111.3) was ordered as a codon-optimized gBlock gene fragment. A codon-optimized variant of the cDNA of CD47 transcript variant 2 (RefSeq: NM_198793.2), the most abundant transcript variant of CD47 containing the long 3′ untranslated region 45 was generated as a gBlock gene fragment that encodes a C-terminal hemagglutinin tag. The lentiviral pCDH-CMV-MCS-EF1-Puro vector encoding C-terminal His-tagged human wild-type QPCTL (ENST00000012049.9) and the QPCTL (D326E) mutant were generated by cloning gBlock gene fragments digested with SpeI and EcoR1 into pCDH-CMV-MCS-EF1-Puro digested with NheI and EcoRI. All other constructs were cloned into the pCDH-CMV-MCS-EF1-Puro (CD510-B1) vector containing a puromycin selection cassette, or in the pCDH-CMV-MCS-mPGK-BSR vector (provided by R. Agami; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands) containing a blasticidin selection cassette using the restriction sites EcoRI and NotI. Constructs were verified by Sanger sequencing.
CRISPR/Cas9-mediated generation of CD47 and QPCTL knockout cells. To generate CD47-and QPCTL-knockout HAP1 cells, cells were co-transfected with PX330 vector encoding single-guide RNA (sgRNA) targeting the QPCTL or CD47 gene and a plasmid containing an expression cassette for a guide RNA targeting the zebrafish Tia1l gene (5′-GGTATGTCGGGAACCTCTCC-3′ (SEQ ID NO: 5)) followed by a cytomegalovirus (CMV) promoter sequence driving expression of a blasticidin resistance gene flanked by two Tia1l target sites 46 . Co-transfection of these plasmids occasionally leads to the incorporation of the blasticidin resistance cassette at the site of the targeted genomic locus by nonhomologous end joining, rendering cells resistant to blasticidin while also providing a genomic tag at the site of mutation. At 4 d after DNA transfection, culture medium was supplemented with 20 µg ml -1 blasticidin (Invivogen). Surviving colonies were clonally expanded and their mutations and/or genomic incorporation of the blasticidin resistance gene were verified by PCR and Sanger sequencing.
To Her2-expressing Ba/F3 cells were generated by retroviral transduction with human HER2 (pMX-puro-Her2), and positive clones were selected using puromycin. To generate Ba/F3-Her2 CD47 and QPCTL-knockout cells, nucleofection was used to deliver pLentiCRISPR v.2 vectors encoding sgRNA targeting either the murine QPCTL or CD47 gene, together with a plasmid containing a Cas9, blasticidin resistance and green fluorescent protein (GFP) expression cassette. At 1 d after nucleofection, culture medium was supplemented with 2 μg ml -1 blasticidin for 2 d. Selected cells were expanded and sorted to obtain bulk knockout populations. Next, single cells were isolated and expanded to obtain clonal knockout populations.
Gene disruption was validated by sequence analysis of the relevant gene locus by TIDE analysis 47 and, in case of CD47, by flow cytometry.
Generation and analysis of CD47-and QPCTL-overexpressing cells. A375
wild-type and QPCTL-knockout cells (clone 4.1) were transduced with a lentiviral pCDH-Puro vector containing cDNA encoding CD47 plus a C-terminal hemagglutinin tag (CD47-HA), including the 3′ long untranslated region of CD47. At 2 d after transduction, cells were selected with 2 μg ml -1 puromycin for 2-3 d. A375 QPCTL-knockout cells (clones 4.1 and 4.6), A431 QPCTL-knockout cells (clones 6 and 11) and A549 QPCTL-knockout cells (clones 3 and 9) were transduced with a lentiviral pCDH-Puro vector containing cDNA encoding human QPCTL(1)-FLAG (and also QPCTL(2)-FLAG in case of A375), as described above. B16F10 QPCTL-knockout cells (bulk KO#1 and KO#2) and Ba/F3-Her2 QPCTL-knockout cells (clones 8 and 30) were transduced with a lentiviral vector containing cDNA encoding mouse QPCTL-FLAG, as described above. At 2 d after transduction, cells were selected with 2 μg ml -1 puromycin for 2-3 d.
SEN177 and PQ912 treatment.
For flow cytometry analysis, cells were plated in triplicate in the appropriate medium containing 0.03% (v/v) DMSO (vehicle control), 10 μM SEN177 (Sigma Aldrich) or 10 μM PQ912 (Syncom). DMSO or inhibitor was refreshed every day and after 4 d, cells were analyzed by flow cytometry.
Immunoprecipitation, SDS-polyacrylamide gel electrophoresis, western blot analysis and isoelectric focusing. For SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis, cells were plated to obtain 70-90% confluence the next day. On the day of analysis, cells were washed with PBS and lysed with RIPA buffer (1% Triton, 0.1% sodium deoxycholate (DOC), 0.1% SDS, 1 mM EDTA, 10 mM Tris, pH 8.0, 140 mM NaCl) supplemented with protease inhibitor cocktail (Roche) and 1 mM PMSF (Sigma). After a 30-min incubation on ice, cell lysates were centrifuged at 13,300g for 20 min at 4 °C. Supernatants were subsequently processed and protein concentrations were measured using the Pierce BCA Protein Assay kit according to the manufacturer's instructions (Thermo Fisher Scientific). Equal amounts of protein supernatants were subsequently processed using a Novex NuPAGE Electrophoresis system (Thermo Fisher Scientific) and Trans-Blot Turbo Transfer system (Bio-Rad) according to the manufacturers' instructions. QPCTL(1)-FLAG or QPCTL(2)-FLAG expression was detected using anti-FLAG M2 (Sigma) (1:1,000 dilution) and anti-mouse HRP (1:10,000 dilution). For immunoprecipitation and pulse-chase analysis, wild-type A375 cells, QPCTL-knockout cells overexpressing CD47-HA, or CD47 KO cells were plated to obtain 70-90% confluence the next day and, where indicated, treated with 10 μM SEN177 inhibitor for 16 h. On the day of analysis, cells were starved in methionine-and cysteine-free medium for 1 h at 37 °C. , 400102) , anti-human CD47 antibody B6H12.2 (Novus, NBP2-31106) and purified anti-human CD47 antibody CC2C6 (Biolegend, 323102) were bound to protein-G-coated Dynabeads (Thermo Fisher Scientific) according to the manufacturer's instructions. Protein lysates were incubated with mouse IgG1 kappa isotype control-bead mixtures for 1 h at 4 °C to reduce nonspecific binding. Next, precleared protein supernatants were incubated with bead-bound anti-human CD47 B6H12.2 or anti-human CD47 CC2C6 at 4 °C overnight. Immunoprecipitates were either left untreated, treated with endoglycosidase H (EndoH, New England Biolabs), or treated with N-glycosidase F (PNGase F, New England Biolabs) according to the manufacturer's instructions. Next, imunoprecipitates were heated at 50 °C for 10 min in 2× Laemmli buffer and analyzed using a Novex NuPAGE gel electrophoresis system (Thermo Fisher Scientific). Gels were treated with 1 M sodium salicylate, pH 5.6, before being dried and then analyzed on Fujifilm BAS-MP phosphorimager screens at 4 °C. Screens were analyzed on a Typhoon FLA 9500 laser scanner.
One-dimensional IEF was performed essentially as described 48 . Immunoprecipitates from indicated cell lines were prepared as described above and were eluted with 30 μl IEF buffer (9.0 M urea, 2% Triton X-100, 2% (v/v) ampholite, pH 3-10, 5% β-mercaptoethanol), and samples were analyzed on freshly prepared IEF gels (9.5 M urea, 2% Triton X-100, 4.5% acrylamide and 0.24% bis-acrylamide, 4% ampholite, pH 5-7, 1% ampholite, pH 3-10, and 0.4% ampholite, pH 6.5-9), which were run for 16 h. Gels were fixed with 10% acetic acid and 45% methanol and were treated with 1 M Na salicylate, pH 5.6, before drying. Gels were analyzed on phosphorimager screens at 4 °C or on Amersham Hyperfilm ECL (GE Healthcare) at -80 °C. The phosphorimager screens were analyzed on a Typhoon FLA 9500 laser scanner and the films were developed in a Kodak X-omat 2000 processor.
Generation of genetically labeled Raji Turquoise-LMNB1. The LMNB1 coding sequence without start codon was amplified by PCR with BglII forward primer and MfeI reverse primer (Invitrogen), cloned into the BglII-EcoRI site of pE-Turquoise-C1 (Takara Bio), and sequence verified. After this, the AgeI-SalI digested Turquoise-LMNB1 fragment was cloned into the vector pRRL PPT SFFV GFP prester SIN, in which GFP was removed by AgeI and partial SalI digestion. Monocyte isolation was performed by gradient centrifugation on Percoll (Pharmacia), followed by negative selection of monocytes by magnetic-activated cell separation (Miltenyi Biotec). Freshly isolated monocytes were cultured for 7-8 d at 37 °C and 5% CO 2 in IMDM medium supplemented with 10% FCS, 100 U ml -1 penicillin, 100 µg ml -1 streptomycin, 2 mM l-glutamine (Gibco Invitrogen) and 20 ng ml -1 human macrophage colony-stimulating factor (M-CSF, eBioscience) to allow differentiation into macrophages. At 1 d before phagocytosis assays, 10 ng ml -1 of recombinant human IL-10 (PeproTech) was added. On the day of assay, culture medium was replaced by fresh IMDM medium containing 0.5% FCS, in the presence, where indicated, of anti-SIRPα 12C4 or F(ab′) 2 fragment of anti-CD47 B6H12 (ref. 7 ). Raji Turquoise-LMNB1 cells were cultured 5 d before the experiment in the presence of either vehicle control (DMSO) or SEN177 (10 µM). Inhibition of SIRPα binding to CD47 on target cells by prior culture in the presence of SEN177 was monitored by flow cytometry at the end of each target cell culture. For antibody-dependent cellular phagocytosis, target cells were first labeled with the membrane dye DiIC 18 (5) solid (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt) (Thermo Fisher Scientific) for 30 min at 37 °C, washed with PBS and then incubated for 3 h in the presence or absence of the opsonizing anti-CD20 rituximab (2 µg ml -1 ) and macrophages (effector/target cell ratio of 1:2). Cells were washed with PBS and detached using citric saline solution (135 mM potassium chloride, 15 mM sodium citrate, Sigma-Aldrich). To discriminate between macrophages and Raji Turquoise-LMNB1 cells during analysis, cells were incubated with phycoerythrin (PE)-labeled anti-human CD11b, M1/70 (eBioscience). Internalization of tumor cells by macrophages was determined by imaging flow cytometry (Image Stream, Amnis, EMD, Millipore) using the following gating strategy: in-focus macrophages were gated based on CD11b expression. Subsequently, the fraction of CD11b
+ macrophages positive for Raji Turquoise-LMNB1 was analyzed based on fluorescence in the 405-nm channel (analysis software IDEAS, Amnis Corporation). The extent of phagocytosis was evaluated both as the percentage of Raji Turquoise-LMNB1-positive CD11b
+ macrophages, and as mean fluorescence intensity of CD11b
+ cells in the 405-nm channel.
In vitro antibody-dependent cellular cytotoxicity. For ADCC assays of 51 Cr-labeled A431 target cells by human effector cells, neutrophils were isolated as described 49 . After isolation, neutrophils were cultured for 30 min in HEPESbuffered saline solution (containing 132 mM NaCl, 6.0 mM KCl, 1.0 mM CaCl 2 1.0 mM MgSO 4 , 1.2 mM potassium phosphate, 20 mM HEPES, 5.5 mM glucose, and 0.5% (w/v) human serum albumin, pH 7.4) in the presence of 10 ng ml -1 clinical-grade recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) at a concentration of 5 × 10 6 cells per ml. Indicated target cells were labeled with 100 μCi ADCC of 51 Cr-labeled Ba/F3-Her2 target cells by human effector cells has been described 50 . Briefly, 1 × 10 6 target cells were labeled with 100 µCi (3.7 MBq) 51 Cr for 2 h. After extensive washing, cell numbers were adjusted to 1 × 10 5 cells per ml. The PMN fraction from peripheral blood of healthy donors (UMC Utrecht) was isolated by Ficoll/Histopaque separation (GE Healthcare; Sigma-Aldrich). Effector cells and target cells were added to round-bottom microtiter plates (Corning Incorporated) (effector/target cell ratio of 40:1), in the presence of the indicated concentration of IgA1 anti-Her2. After 4 h incubation at 37 °C, 51 Cr release was measured. Percentage specific lysis was calculated using the formula described above. The production and activity of IgA1 anti-Her2 has been described 51 . For experiments with SEN177, 10 μM SEN177 or vehicle control (DMSO) was added 3 d before the assay, added freshly on the day of the assay, and kept present during the assay. All experiments were performed in triplicate.
ADCC of 51 Cr-labeled Ba/F3-Her2 target cells by mouse effector cells was carried out as described 52 . In brief, to obtain mouse effector cells, blood was collected from pegylated granulocyte colony-stimulating factor-stimulated human FcαRI transgenic Balb/c mice from the retro-orbital plexus into lithium-heparin tubes. Erythrocytes were lysed by incubation in water for 30 min, and total leukocytes were resuspended in medium (half the volume of the original blood volume). Some 50 μl of total leukocytes, containing ~70% PMNs, were added per well. . For experiments using homogenous cell populations, Ba/F3-Her2 cells and Ba/F3-Her2 QPCTLknockout cells were labeled with 0.8 μM CT violet. Directly after injection of tumor cells, mice received PBS or 100 μg IgA1 anti-Her2 by i.p. injection. At 16 h after injection, mice were euthanized, the peritoneal cavity was washed with PBS containing 5 mM EDTA, and the absolute number of Ba/F3-Her2, Ba/F3-Her2 CD47-knockout, and Ba/F3-Her2 QPCTL-knockout cells was determined by flow cytometry using TruCount tubes (BD Biosciences). Indicated effector cell types were measured in the peritoneum by staining with the indicated antibodies and quantification relative to a constant amount of sulfate latex beads (Thermo Fisher Scientific). For the depletion of neutrophils, 200 μg of anti-mouse Ly6G (1A8, BXCell) was injected i.p. into mice on day −2 and day 0 of the experiment.
Intracellular cytokine production by human T cells. Human peripheral blood T cells (Sanquin Blood Supply) were activated and transduced with a retroviral vector encoding the CDK4 R24C-specific T cell receptor, essentially as described 53 . After transduction, T cells were cultured for 7-14 d in RPMI containing 5% human serum (Sigma), supplemented with 10 ng ml -1 IL-15 (Peprotech) and 50 U ml -1 IL-2 (Novartis), followed by a 4-d culture period in control (DMSO)-or SEN177-containing (10 μM) medium. Activity of SEN177 was confirmed by comparison of the αhCD47-CC2C6/αCD47-B6H12 ratio in SEN177-treated cells and control (DMSO)-treated cells, as analyzed by flow cytometry. Expression of the CDK4 R24C-specific T cell receptor was confirmed by flow cytometry (data not shown). JY cells were pulsed with CDK4 R24C peptide at indicated concentrations, or as a control with MART-1 26-35 A→L peptide, for 1 h at 37 °C. Next, 2 × 10 5 transduced T cells were incubated with 2 × 10 5 peptide-pulsed JY Letters NaTURE MEDICINE cells or nonpulsed JY cells in the presence of 1 μl ml -1 brefeldin A (GolgiPlug, BD Biosciences) for 5 h at 37 °C and 5% CO 2 . Next, cells were washed and stained with specific antibodies as described above, and analyzed for cytokine production as determined by flow cytometry.
In vitro tumor cell killing by human T cells. Human HLA-A*02:01-positive melanoma lines that carry (NKIRTIL006) or lack (A375) a mutant CDK4 allele were plated in 96-well plates (Greiner Bio-One) and labeled with 100 μCi 51 Cr (Amersham) for 1 h at 37 °C. Cells were washed with RMPI containing 10% FCS and penicillin-streptomycin to remove unincorporated 51 Cr before addition of CDK4-specific T cell receptor-transduced T cells at the indicated target/ T cell ratios. Cells were incubated for 4 h at 37 °C in 200 μl medium. Next, plates were centrifuged for 1 min at 246g and 50 μl medium was harvested, plated on LumaPlate-96 plates (Perkin Elmer), dried overnight and analyzed on a Top Counter (Perkin-Elmer). Specific cytotoxicity was calculated according to the formula described above.
In vitro proliferation, phenotypic analysis and cytokine secretion of human T cells. Peripheral blood lymphocytes from two donors were stimulated with anti-CD3 and anti-CD28 beads (Thermo Fisher Scientific) at a 2:1 bead/T cell ratio. Cells were cultured for a 2-week period in RPMI with 5% human serum (HS), IL-2 (50 IU ml -1 ) and IL-15 (10 ng ml -1 ) in the presence of SEN177 (10 μM) or control (DMSO). Every 2 to 3 d, cells were counted and replated at a density of 0.25 × 10 6 cells ml -1 . Surface expression of phenotypic markers was analyzed on day 0, 5, 10 (data not shown) and 14 with the indicated antibodies. On day 14, T cells were re-stimulated with anti-CD3 and anti-CD28 beads (1:1 bead/T cell ratio), supernatants were collected 38 h after stimulation, and levels of IL-2, IL-4, IL-6, IL-10, IFNγ, IL17A and TNFα were measured using the Cytometric Bead Array Human Th1/Th2/Th17 Cytokine kit (BD Biosciences), according to the manufacturer's protocol.
In vitro induction of antigen-specific T cells by autologous antigen-presenting cells.
In vitro T cell induction was performed under three conditions: (1) T cell induction by matured autologous dendritic cells (DCs) in the presence of control (DMSO), (2) T cell induction by matured autologous dendritic cells, in which T cell induction was performed in the presence of 10 μM SEN177 or (3) T cell induction by matured autologous dendritic cells, in which both the maturation of autologous DCs and T cell induction was performed in the presence of 10 μM SEN177.
For the maturation of autologous DCs, monocytes from a healthy donor were isolated by CD14 selection using LS MACS columns (Miltenyi Biotec) and the purity of the obtained population was assessed by flow cytometry. Next, CD14 + cells were plated in CellGenix GMP Dendritic Cell medium supplemented with 400 U ml -1 IL-4 (CellGenix) and 800 U ml -1 GM-CSF (CellGenix) to generate immature DCs. After 5 d, immature DCs were loaded with he following long and short peptides: EBV BMLF-1 (RMQAIQNAGLCTLVAMLEETIFWLQ), CMV pp65 (WQAGILARNLVPMVATVQGQNLKYQ), EBV BRLF-1 (IACPI VMRYVLDHLIVVTDRFFIQA) and MART-1 (HSYTTAEELAGIGILTVILG VLLLI), in which the sequences in bold reflect previously identified CD8 + T cell epitopes. After 1 h, DC maturation mix containing 400 U ml -1 IL-4, 800 U ml -1 GM-CSF, 10 ng ml -1 TNF-α (CellGenix), 10 ng ml -1 IL-1β (CellGenix), 10 ng ml -1 IL-6 (CellGenix) and 0.5 μg ml -1 prostaglandin E1 (Pfizer) was added to DC medium, and DCs were cultured for 2 d.
For T cell inductions, mature peptide-loaded DCs were cultured with autologous human PBMCs in a 1:10 DC/human PBMC ratio in 20% AIM V Serum Free medium (Thermo Fisher Scientific) and 80% RPMI (Life Technologies), supplemented with 5% human serum, 1% GlutaMAX (Thermo Fisher Scientific), penicillin-streptomycin, 5 ng ml -1 IL-7 (CellGenix) and 5 ng ml -1 IL-15 (CellGenix). Fresh IL-7, IL-15, and control or SEN177 was added every 2-3 d, and cells were split twice a week.
After 11 d, the percentage of T cells specific for the indicated CMV, EBV and MART-1 epitopes was determined by combinatorial pMHC-multimer staining as described 54 , and data were compared to values at baseline. The functionality of induced T cell populations was examined in a co-culture after 6 d. Induced T cell populations were cultured in the presence of autologous peptide-loaded DCs for 5 h, and then analyzed for intracellular cytokine production, as determined by flow cytometry. After 12 d, the surface expression of phenotypic markers was analyzed by flow cytometry, as described above.
In vitro differentiation of human T cells into Th17 cells. CD4
+ T cells were isolated from human peripheral blood using the Dynabeads Untouched Human CD4 T Cells kit (Thermo Fisher Scientific), according to the manufacturer's protocol. Purity of the obtained CD4
+ T cell population was analyzed by flow cytometry (donor 1, 93%; donor 2, 94%). Next, CD4
+ T cells were cultured at a density of 0.5 × 10 6 cells per ml in RPMI medium containing 10% HS, anti-CD3 and anti-CD28 beads (2:1 bead/T cell ratio), 10 ng ml -1 IL-6 (R&D Systems), 10 ng ml -1 IL-1β (R&D Systems), 10 ng ml -1 TGF-β1 (R&D Systems), 10 ng ml -1 IL-23 (R&D Systems), 10 μg ml -1 anti-IL-4 (MP4-25D2, BD Biosciences) and 10 μg ml -1 anti-IFNγ (B27, BD Biosciences) (Th17 differentiation medium). Medium was refreshed every 2-3 d and cells were split on days 4 and 7. On days 7 and 10, cells were harvested and re-stimulated with 50 ng ml -1 phorbol 12-myristate 13-acetate (BD Biosciences) and 1 μg ml -1 ionomycin (BD Biosciences) in the presence of 1 μl ml -1 brefeldin A for 5 h at 37 °C and 5% CO 2 . Next, cells were harvested and stained using the indicated antibodies, and the percentage of IL17A Statistical analysis. Data are reported as mean ± s.d. as specified. Statistical significance was determined using Student's t-test or one-way analysis of variance (ANOVA) as inidicated (GraphPad Prism version 7). All Student's t-tests were two-sided under the assumption of equal variance between samples. All one-way ANOVA tests were corrected for multiple comparisons using statistical hypothesis testing. Differences were considered statistically significant if P < 0.05. The n values used to calculate statistics, the type of replicates and the relevant significant P values are noted in the figure legends. 
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Sample size
No expected effect size was pre-specified. Generally accepted samples sizes were used, with a significant difference between conditions indicating that the sample size is sufficient.
Data exclusions In one in vivo experiment with WT and QPCTL KO cells, one mouse has been excluded due to a puncture in the muscle layer of the stomach, as no peritoneal lavage could be performed after this (so no analysis could be performed on this mouse). In analysis of chromium release assays, large outliers within triplicate measurements have been excluded. In analysis of ADCP experiment with Raji cells, one large outlier (4 times measured) has been excluded. Exclusion criteria were pre-established by historical data.
Replication
Every figure states how many times each experiment had been repeated. To ensure experiments could be reliably reproduced, fully independent experiments were performed as defined by commonly accepted standards.
Randomization Allocation was random
Blinding
Experiments were not performed blindly, as preparation of the cell mixes for in vivo experiments, and the actual in vivo experiments were prepared by the same person due to logistical reasons.
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Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Cell lines were cultured, and when attaching cells, harvested by trypsin EDTA treatment. All cells were stained in PBS containing 0.5% w/v bovine serum albumin and 0.2% w/v sodium azide.
Instrument BD LSRII, Fortessa or FACSCantoII
Software
Data were collected using BD FacsDiva and analyzed using FlowJo
Cell population abundance B16F10 CD47 KO and QPCTL KO bulk population were sorted after transient transfection with sgRNA's targeting CD47 or QPCTL locus. Sorting strategy was based on αmCD47-MIAP301 negative/mSIRPα-Fc negative (for CD47 KO) or αmCD47-MIAP301 positive/mSIRPα-Fc low.
Gating strategy
Experiments were gated first by morphology to exclude cell debris, then in case of non-permeabilized cells by DAPI or PI negative to exclude dead cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
